Success Metrics

Clinical Success Rate
50.0%

Based on 1 completed trials

Completion Rate
50%(1/2)
Active Trials
0(0%)
Results Posted
100%(1 trials)
Terminated
1(20%)

Phase Distribution

Ph phase_3
5
100%

Phase Distribution

0

Early Stage

0

Mid Stage

5

Late Stage

Phase Distribution5 total trials
Phase 3Large-scale testing
5(100.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

50.0%

1 of 2 finished

Non-Completion Rate

50.0%

1 ended early

Currently Active

0

trials recruiting

Total Trials

5

all time

Status Distribution
Active(1)
Completed(1)
Terminated(1)
Other(2)

Detailed Status

unknown2
Completed1
Not yet recruiting1
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
5
Active
0
Success Rate
50.0%
Most Advanced
Phase 3

Trials by Phase

Phase 35 (100.0%)

Trials by Status

unknown240%
completed120%
not_yet_recruiting120%
terminated120%

Recent Activity

0 active trials
Showing 5 of 5
terminatedphase_3

Tislelizumab Monotherapy Versus Salvage Chemotherapy for Relapsed/Refractory Classical Hodgkin Lymphoma

NCT04486391
not_yet_recruitingphase_3

A Study of XY0206 Versus Salvage Chemotherapy In Patients With Relapsed or Refractory AML With FLT3-ITD-Mutation (ALIVE)

NCT05876832
unknownphase_3

A Study of SKLB1028 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory (R/R) AML With FLT3-Mutated

NCT04716114
unknownphase_3

Surgery or Chemotherapy in Recurrent Ovarian Cancer (SOC 1 Trial)?

NCT01611766
completedphase_3

(QuANTUM-R): An Open-label Study of Quizartinib Monotherapy vs. Salvage Chemotherapy in Acute Myeloid Leukemia (AML) Subjects Who Are FLT3-ITD Positive

NCT02039726

Clinical Trials (5)

Showing 5 of 5 trials
NCT04486391Phase 3

Tislelizumab Monotherapy Versus Salvage Chemotherapy for Relapsed/Refractory Classical Hodgkin Lymphoma

Terminated
NCT05876832Phase 3

A Study of XY0206 Versus Salvage Chemotherapy In Patients With Relapsed or Refractory AML With FLT3-ITD-Mutation (ALIVE)

Not Yet Recruiting
NCT04716114Phase 3

A Study of SKLB1028 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory (R/R) AML With FLT3-Mutated

Unknown
NCT01611766Phase 3

Surgery or Chemotherapy in Recurrent Ovarian Cancer (SOC 1 Trial)?

Unknown
NCT02039726Phase 3

(QuANTUM-R): An Open-label Study of Quizartinib Monotherapy vs. Salvage Chemotherapy in Acute Myeloid Leukemia (AML) Subjects Who Are FLT3-ITD Positive

Completed

All 5 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
5